- Current report filing (8-K)
2009年11月19日 - 5:58AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
November
13, 2009
Date of
Report (Date of earliest event reported)
NEUROGEN
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of
incorporation)
|
0-18311
(Commission
File Number)
|
22-2845714
(I.R.S.
Employer Identification No.)
|
45
Northeast Industrial Road
Branford,
Connecticut 06405
(Address
of principal executive offices) (Zip Code)
(203)
488-8201
(Registrant's
telephone number, including area code)
None
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item
5.02(b)
Departure of Directors
or Principal Officers; Election of Directors; Appointment of Principal
Officers
On
November 13, 2009, Kenneth Sprenger’s employment as Senior Vice President,
Clinical Development and Operations of Neurogen Corporation was terminated
without cause. Under Dr. Sprenger’s employment agreement, dated as of
March 27, 2009, he was entitled to receive, and the Company has paid to him, a
severance payment of $375,000 equal to twelve months of his base salary and
target bonus.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
NEUROGEN
CORPORATION
|
|
(Registrant)
|
|
|
|
By:
/s/ THOMAS A. PITLER
|
|
Name:
Thomas A. Pitler
|
Date:
November 18, 2009
|
Title:
Senior Vice President and Chief Business and Financial
Officer
|
Neurogen (NASDAQ:NRGN)
過去 株価チャート
から 5 2024 まで 6 2024
Neurogen (NASDAQ:NRGN)
過去 株価チャート
から 6 2023 まで 6 2024